Page - (000400) - in Biomedical Chemistry: Current Trends and Developments

Nano, 5(1), 413-423. Fang, J., Nakamura, H., Maeda, H. (2011). The epr effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Advanced Drug Delivery Reviews, 63(3), 136-151. Farokhzad, O. C., Langer, R. (2009). Impact of nanotechnology on drug delivery. ACS Nano, 3(1), 16-20. Fasol, U., Frost, A., Buchert, M., et al. (2012). Vascular and pharmacokinetic effects of endotag-1 in patients with advanced cancer and liver metastasis. Annals of Oncology, 23(4), 1030- 1036. Fass, L. (2008). Imaging and cancer: A review. Molecular Oncology, 2(2), 115-152. Fattal, E., Barratt, G. (2009). Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering rna. British Journal of Pharmacology, 157(2), 179-194. Fernandez-Fernandez, A., Manchanda, R., McGoron, A. J. (2011). Theranostic applications of nanomaterials in cancer: Drug delivery, image-guided therapy, and multifunctional platforms. Applied Biochemistry and Biotechnology, 165(7-8), 1628-1651. Ferrari, M. (2005). Cancer nanotechnology: Opportunities and challenges. Nature Reviews Cancer, 5(3), 161-171. Ferris, R. L., Jaffee, E. M., Ferrone, S. (2010). Tumor antigen-targeted, monoclonal antibody- based immunotherapy: Clinical response, cellular immunity, and immunoescape. Journal of Clinical Oncology, 28(28), 4390-4399. Fifis, T., Gamvrellis, A., Crimeen-Irwin, B., et al. (2004). Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors. Journal of Immunology, 173(5), 3148-3154. Flacher, V., Tripp, C. H., Stoitzner, P., et al. (2010). Epidermal langerhans cells rapidly capture and present antigens from c-type lectin-targeting antibodies deposited in the dermis. Journal of Investigative Dermatology, 130(3), 755-762. Foged, C., Brodin, B., Frokjaer, S., et al. (2005). Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. International Journal of Pharmacuetics, 298(2), 315-322. Foged, C., Sundblad, A., Hovgaard, L. (2002). Targeting vaccines to dendritic cells. Pharmaceutics Research, 19(3), 229-238. Fonseca, N. A., Gomes-da-Silva, L. C., Moura, V., et al. (2014). Simultaneous active intracellular delivery of doxorubicin and c6-ceramide shifts the additive/antagonistic drug interaction of non-encapsulated combination. Journal of Controlled Release, 196(0), 122-131. Foster, S., Duvall, C. L., Crownover, E. F., et al. (2010). Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances cd8 t-cell production and prophylactic vaccine efficacy. Bioconjugate Chemistry, 21(12), 2205-2212. Gajewski, T. F., Woo, S. R., Zha, Y., et al. (2013). Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Current Opinion on Immunology, 25(2), 268-276. Garlapati, S., Garg, R., Brownlie, R., et al. (2012). Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with cpg oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene